Literature DB >> 32527493

Superselective intra-arterial chemotherapy treatment for retinoblastoma: clinical experience from a tertiary referral centre.

Bilge Batu Oto1, Ahmet Murat Sarıcı2, Osman Kızılkılıç3.   

Abstract

OBJECTIVE: To evaluate the treatment outcomes of an alternative retrograde superselective ophthalmic artery catheterization (intra-arterial chemotherapy [IAC]), while treating retinoblastoma patients.
METHODS: A retrospective review of IAC for 21 treatment-naïve eyes (21 patients, primary group) and 10 eyes of previously treated 9 patients (secondary group). Statistical analysis was performed using Number Cruncher Statistical System 2007, Kaplan-Meier survival analysis, and Fisher's exact test.
RESULTS: Total fluoroscopy time ranged from 3 to 12 minutes. Globe salvage was 71.4% (15/21 eyes) and 80% (8/10 eyes) in the primary and secondary groups, respectively. Globe salvage rates were recorded as 100%, 100%, 70%, and 0% for group B, C, D, and E patients, respectively.
CONCLUSIONS: Retrograde IAC is effective in tumour control with shorter fluoroscopy time and acceptable complication rates both for naïve and treated patients. Furthermore, controlling retinoblastoma in advanced group D eyes was efficacious.
Copyright © 2020 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID: 32527493     DOI: 10.1016/j.jcjo.2020.04.009

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


  2 in total

1.  Multimodal imaging of a sporadic retinal astrocytic hamartoma simulating retinoblastoma in a newborn.

Authors:  Bilge Batu Oto; Aslihan Yilmaz Çebi; Oguzhan Kiliçarslan; Ahmet Murat Sarici
Journal:  GMS Ophthalmol Cases       Date:  2022-05-20

Review 2.  Treatment of Retinoblastoma: What Is the Latest and What Is the Future.

Authors:  Paula Schaiquevich; Jasmine H Francis; María Belén Cancela; Angel Montero Carcaboso; Guillermo L Chantada; David H Abramson
Journal:  Front Oncol       Date:  2022-04-01       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.